Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Ryder

Showing results (241-250 of 266) with videos related to

Pageof 27
Sort By:
Plos One|January 23, 2023
Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virusAminata Sy, Leanne McCabe, Emma Hudson, et al.
Ebiomedicine|May 24, 2022
The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort studyDavid E J Jones, Aaron Wetten, Ben Barron-Millar, et al.
Gut Microbes|May 16, 2023
Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitisLaura Martinez-Gili, Alexandros Pechlivanis, Julie A K McDonald, et al.
ESMO Open|June 25, 2026
Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trialA Lamarca, D H Palmer, H S Wasan, et al.
Hepatology (Baltimore, Md.)|February 24, 2018
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trialGraham R Foster, Kosh Agarwal, Matthew E Cramp, et al.
Scientific Reports|October 29, 2021
Mapping of population disparities in the cholangiocarcinoma urinary metabolomeMunirah Alsaleh, Zoe Leftley, Thomas O'Connor, et al.
Clinical Medicine (London, England)|January 22, 2021
Long-term outcomes of liver transplant recipients followed up in non-transplant centres: Care closer to homeCynthia Tsien, Huey Tan, Sowmya Sharma, et al.
Addiction (Abingdon, England)|January 30, 2019
The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in EnglandGraham I Harrison, Karen Murray, Roxanne Gore, et al.
Science (New York, N.Y.)|October 19, 2023
A luminous fast radio burst that probes the Universe at redshift 1S D Ryder, K W Bannister, S Bhandari, et al.
Journal of Viral Hepatitis|November 14, 2018
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysisSteven Flamm, David Mutimer, Armen Asatryan, et al.
Pageof 27

Showing results (241-250 of 266) with videos related to

Sort By:
Pageof 27
Plos One|January 23, 2023
Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virusAminata Sy, Leanne McCabe, Emma Hudson, et al.
Ebiomedicine|May 24, 2022
The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort studyDavid E J Jones, Aaron Wetten, Ben Barron-Millar, et al.
Gut Microbes|May 16, 2023
Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitisLaura Martinez-Gili, Alexandros Pechlivanis, Julie A K McDonald, et al.
ESMO Open|June 25, 2026
Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trialA Lamarca, D H Palmer, H S Wasan, et al.
Hepatology (Baltimore, Md.)|February 24, 2018
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trialGraham R Foster, Kosh Agarwal, Matthew E Cramp, et al.
Scientific Reports|October 29, 2021
Mapping of population disparities in the cholangiocarcinoma urinary metabolomeMunirah Alsaleh, Zoe Leftley, Thomas O'Connor, et al.
Clinical Medicine (London, England)|January 22, 2021
Long-term outcomes of liver transplant recipients followed up in non-transplant centres: Care closer to homeCynthia Tsien, Huey Tan, Sowmya Sharma, et al.
Addiction (Abingdon, England)|January 30, 2019
The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in EnglandGraham I Harrison, Karen Murray, Roxanne Gore, et al.
Science (New York, N.Y.)|October 19, 2023
A luminous fast radio burst that probes the Universe at redshift 1S D Ryder, K W Bannister, S Bhandari, et al.
Journal of Viral Hepatitis|November 14, 2018
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysisSteven Flamm, David Mutimer, Armen Asatryan, et al.
Pageof 27